Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business escalating. We need to look for management's own words conveying a comparison against their own recent past, that it's already real and recurring, and that it's early. Let's review the transcript. The call covers HeartBeam's Q4 2022 results. Management discusses products: HeartBeam AIMI (software) and HeartBeam AIMIGo (device). They talk about FDA submissions, partnerships, acquisitions, etc. Key points: They have a product pipeline. They mention partnerships with Evolve Manufacturing, acquisition of LIVMOR assets, patents, etc. But do they talk about deals, orders, contracts, customers, or programs getting bigger over time? The question is about the size of engagements, not just revenue growth. I see no mention of specific deals, orders, or contracts. They talk about market opportunities, product development, FDA submissions, and go-to-market strategy. They mention "direct pay market segments" and a phased approach. But there's no discussion of the size of individual deals or how they've grown. They mention "we continue to engage with potential customers and partners" but no specifics. They talk about the acquisition of LIVMOR assets, but that's an acquisition, not a customer deal. They talk about partnerships with Evolve Manufacturing, but that's a manufacturing partnership, not a customer order. The question is about successive engagements of the same kind coming in at progressively larger size. For example, if they were selling devices, are the orders getting bigger? There's no such description. Management does talk about product pipeline and future products, but not about deal size escalation. Thus, the answer is NO. We need to be careful: The question asks if management conveys that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago. There is no such statement. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.